Pembrolizumab combined with gemcitabine-based chemoradiation is feasible and effective in patients with muscle-invasive bladder cancer (MIBC).

A first-in-human trial of intravesical BH011, a novel docetaxel formulation, in patients with high risk non-muscle invasive bladder cancer (HR-NMIBC) after BCG failure: Results from a phase 1 study.

Perioperative management for muscle invasive bladder cancer (MIBC) includes neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy and risk-adapted adjuvant immunotherapy. More ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk for ...

Muscle-invasive bladder cancer is an aggressive disease generally treated with cystectomy with or without neoadjuvant therapy. Following curative-intent surgery, about 50% of patients develop ...